Good morning, you're tuned in to Markets Desk, and here's what's moving the needle today.
Novo Nordisk is giving investors just enough to work with, narrowing its full-year guidance even as it warns that both profits and sales will still decline in twenty twenty five. The headline, though, belongs to the Wegovy pill, which the company says recorded the fastest consumer take-up in weight-loss drug history. That kind of commercial momentum matters, and it signals the oral GLP-one market has real legs beyond the injectable format that built this category.
Shifting to trade policy, Iran's foreign minister is in Beijing ahead of a potential Trump-Xi summit, and the timing is anything but coincidental. Analysts believe Beijing is positioning its relationship with Tehran as a card to play at the negotiating table, a reminder that the geopolitical and the commercial are inseparable when the world's two largest economies sit down together.
And for American businesses still absorbing the tariff shock, there is some relief in the paperwork. As of April twentieth, importers can file for IEEPA tariff refunds through the new CAPE portal. Small and large companies alike are moving quickly on this, and the amounts at stake are significant enough that legal and trade compliance teams are treating it as a genuine priority.
That's the tape. Markets Desk, signing off the floor.
